First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
Sponsor: Fudan University